Nízkomolekulární hepariny v tromboprofylaxi během indukční chemoterapie u pacientů s mnohočetným myelomem

Východiska:
Pacienti s mnohočetným myelomem mají vysoké riziko tromboembolické nemoci (TEN), zejména během indukční chemoterapie. Cílem studie bylo zjištění vlivu profylaxe nízkomolekulárním heparinem (LMWH) na incidenci tromboembolických komplikací.

Pacienti a metody:
Analyzovali jsme incidenci tromboembolických příhod u 258 pacientů léčených indukční terapií obsahující vinkristin, doxorubicin nebo idarubicin a dexametazon, následovanou stimulační chemoterapií cyklofosfamidem a G-CSF, a vysokodávkovanou chemoterapií melfalanem. Byly porovnány dvě skupiny těchto pacientů podle praktikované tromboprofylaxe. Pacienti v první skupině (kontrolní, n = 140) buď nebyli léčeni, nebo byli léčeni antikoagulační terapií jen po krátkou dobu, zatímco pacienti ve druhé skupině (profylaktická, n = 118) dostávali standardní profylaxi LMWH po celou dobu indukční chemoterapie. U 102 pacientů byl vyhodnocen profylaktický účinek různých dávek LMWH a porovnán s pacienty bez léčby.

Výsledky:
Standardní profylaxe LMWH významně (p < 0,007) snížila riziko TEN ve srovnání s pacienty bez této profylaxe (3,4 % vs 12,9 %). V analýze podskupiny 102 pacientů bylo zjištěno, že vyšší dávka LMWH (> 70 IU/ kg denně) vedla k 100% účinné profylaxi u 28 pacientů, zatímco nižší dávky byly méně efektivní, 3 pacienti z 39 (7,7 %) prodělali hlubokou žilní trombózu. Naproti tomu TEN byla diagnostikována u 5 z 35 (14,3 %) pacientů bez profylaxe.

Závěr:
Profylaxe LMWH vede k významné redukci rizika tromboembolických komplikací během indukční chemoterapie u pacientů s mnohočetným myelomem. Profylaktický efekt LMWH je závislý na dávce.

Klíčová slova:
mnohočetný myelom – tromboembolická nemoc – prevence – nízkomolekulární heparin

Autoři: P. Kessler ¹; L. Pour ²; E. Gregora ³; M. Zemanová ⁴; M. Penka ⁵; M. Brejcha ⁶; Z. Adam ²; J. Bacovsky ⁴; M. Fenclova ⁷; H. Fraňková ^1,8; P. Hausdorf ⁹; L. Walterová ¹⁰; V. Heinzová ¹¹; M. Holikova ¹²; M. Krejci ²; K. Kubackova ¹³; E. Langrová ⁷; V. Maisnar ¹⁴; I. Meluzinova ¹⁵; Y. Stavarova ¹⁶; J. Straub ¹⁷; V. Scudla ⁴; J. Gumulec ¹⁸; J. Ullrychová ¹⁹; R. Hájek ²; For The Czech Myeloma Group
Působiště autorů: Department of Hematology and Transfusion Medicine, Hospital Pelhrimov, Czech Republic ¹; Department of Internal Medicine – Hematooncology, University Hospital Brno, Czech Republic ²; Department of Haematology, University Hospital Kralovske Vinohrady Praha, Czech Republic ³; Third Department of Internal Medicine, University Hospital Olomouc, Czech Republic ⁴; Department of Haematology, University Hospital Brno, Czech Republic ⁵; Department of Haematology, Centre for Thrombosis and Haemostasis, Hospital Novy Jicin, Czech Republic ⁶; Department of Haematology, Hospital Kladno, Czech Republic ⁷; Department of Haematology, Hospital Trebic, Czech Republic ⁸; Department of Internal Medicine, Hospital Cesky Krumlov, Czech Republic ⁹; Department of Haematology, Regional Hospital, Liberec, Czech Republic ¹⁰; Department of Haematology, Hospital Opava, Czech Republic ¹¹; Department of Oncology, Regional Hospital, Liberec, Czech Republic ¹²; Department of Oncology, Charles University Hospital Motol Praha, Czech Republic ¹³; Department of Haematology, Charles University Hospital Hradec Kralove, Czech Republic ¹⁴; Department of Haematology, Hospital Boskovice, Czech Republic ¹⁵; Department of Haematology, T. Bata’s Regional Hospital, Zlin, Czech Republic ¹⁶; First Department of Internal Medicine, General Faculty Hospital, Prague, Czech Republic ¹⁷; Department of Haematology, University Hospital Ostrava, Czech Republic ¹⁸; Department of Haematology, Hospital Decin, Czech Republic ¹⁹
Vyšlo v časopise: Klin Onkol 2011; 24(4): 281-286
Kategorie: Původní práce

Souhrn

Klíčová slova:
mnohočetný myelom – tromboembolická nemoc – prevence – nízkomolekulární heparin

Zdroje

1. Deitcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost 2003; 29(3): 247–258.

2. Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98(5): 1614–1615.

3. Bowcock S, Rassam SM, Ward SM et al. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002; 7(1): 51–53.

4. Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89(7): 826–831.

5. Srkalovic G, Cameron MG, Rybicki L et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101(3): 558–566.

6. Sallah S, Husain A, Wan J et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15(10): 1490–1494.

7. Zangari M, Siegel E, Barlogie B et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100(4): 1168–1171.

8. Zangari M, Barlogie B, Anaissie E et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126(5): 715–721.

9. Zangari M, Barlogie B, Thertulien R et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003; 4(1): 32–35.

10. Rajkumar SV, Blood E, Vesole D et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24(3): 431–436.

11. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357(21): 2123–2132.

12. Minnema MC, Fijnheer R, De Groot PG et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1(3): 445–449.

13. Auwerda JJ, Sonneveld P, de Maat MP et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007; 92(2): 279–280.

14. Zangari M, Saghafifar F, Anaissie E et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13(3): 187–192.

15. Elice F, Fink L, Tricot G et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134(4): 399–405.

16. Geerts WH, Berqqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl 6): 381S–453S.

17. Martin MG, Vij R. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature. Clin Lymphoma Myeloma 2009; 9(4): 320–323.

18. Minnema MC, Breitkreuz I, Auwerda JJ et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18(12): 2044–2046.

19. Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106(1): 35–39.

20. Weber D, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21(1): 16–19.

21. Ikhlaque N, Seshadri V, Kathula S et al. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 2006; 81(6): 420–422.

22. Baz R, Li L, Kottke-Marchant K et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80(12): 1568–1574.

23. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106(13): 4050–4053.

24. Menon SP, Rajkumar SV, Lacy M at al. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 2008; 112(7): 1522–1528.

25. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myleoma: ransomised controlled trial. Lancet 2006; 367(9513): 825–831.

26. Falanga A, Russo L, Vignoli A et al. Prognostic significance for venous thromboembolism (VTE) of hemostatic markers in patients with multiple myeloma (MM) receiving thalidomide. J Thromb Haemost 2007; 5 (Suppl 2): P-M-507.

27. Palumbo A, Cavo M, Bringhen S et al. Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. J Clin Oncol; 2011; 29(8): 986–993.

28. Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 2007; 131(1): 275–277.

29. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22(2): 414–423.